Fate Therapeutics, Inc.

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting to be held in Chicago, IL, May 29 – June 2, 2026 and at the European Congress of Rheumatology being held in London, UK, June 3-6, 2026. Presentation details are as follows: ASCO – American Society of Cancer Oncology Product Candidate: FT836 Title: Preliminary Phase 1 Results of a MICA/B-targeted CAR T-cell Designed to Overcome Solid Tumor Escape Mechanisms and Avoid the Requirement for Conditioning Chemotherapy Session: Developmental Therapeutics—Immunotherapy Poster Presentation Date / Time: Saturday, May 30th, 1:30-4:30 CT. A link to the abstract can be found here: ASCO FATE EULAR - European Congress of Rheumatology Product Candidate: FT819 Title: Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study Supporting Same-Day Discharge Session: Clinical Poster Tours: From pathway to patient – therapeutic advances in Lupus (POS0079) Poster Tour Date / Time: Thursday, June 4th, 9:30 a.m. BST A link to the abstract can be found here: EULAR FATE Product Candidate: FT839 Title: Off-the-Shelf Dual-CAR T-Cell Therapy: Targeting B and T Cells in Autoimmune Disease Without Preconditioning Session: Basic Abstract Sessions: New therapeutic targets in Rheumatoid Arthritis and Sjogren’s (OPO156) Oral Presentation Date / Time: Thursday, June 4th, 8:15 a.m. BST A link to the abstract can be found here: EULAR FATE About FT819 FT819 is an off-the-shelf CD19-targeting chimeric antigen receptor (CAR) T-cell product engineered to improve safety and efficacy. Analogous to master cell banks used to mass produce biopharmaceutical drug products such as monoclonal antibodies, a precisely engineered clonal master induced pluripotent stem cell (iPSC) bank serves as the starting cell source to manufacture FT819, overcoming numerous limitations associated with patient- and donor-sourced CAR T-cell therapies. FT819 is well-defined and uniform in composition, produced at a low cost of goods, and can be stored in inventory for off-the-shelf, on-demand availability to enable access for a broad patient population. This research was additionally made possible by funding from the California Institute for Regenerative Medicine (CIRM), a state agency in California that supports research in regenerative medicine, stem cell therapy, gene therapy, and clinical trials. (Grant number: CLIN2-16303) About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the Company’s plans to submit IND applications for its product candidates, the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials, including in new indications, and additional dose cohorts in ongoing clinical trials of the Company’s product candidates, the availability of data from the Company’s clinical trials and the Company’s plans to provide updates on its clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s progress and plans relating to, and the anticipated timing and outcome of, interactions with the FDA and other regulatory authorities, including its expectations relating to alignment with regulatory authorities on potential registrational pathways for FT819. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and risks relating to regulatory interactions and the outcome of such interactions. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Ryan DouglasFate Therapeutics, Inc.IR@fatetherapeutics.com

Cell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectors NEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue function, reduce inflammation, and support healthier aging overall. That shift in focus has sparked major interest from biotech companies and institutional investors alike. The global cell therapy market was valued at around $4.7 billion in 2023 and is expected to climb past $20 billion by 2030 as more therapies move closer to commercialization. Healthcare companies active in the markets this week include: Avaí Bio, Inc. (OTCQB: AVAI), Geron Corporation (NASDAQ: GERN), BioAge Labs, Inc. (NASDAQ: BIOA), Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), Fate Therapeutics, Inc. (NASDAQ: FATE). At the same time, the broader longevity and anti-aging market continues gaining momentum as aging populations grow worldwide. Researchers are developing next-generation treatments aimed at removing senescent, or "zombie," cells that contribute to aging and disease while also working to regenerate damaged tissue and improve cognitive and physical function later in life. Many of these cell-based approaches are now being combined with gene therapies, immune-focused treatments, and personalized medicine strategies to create more targeted solutions. Industry forecasts suggest the global senolytics and anti-aging pharmaceuticals market could reach approximately $6.39 billion by 2030, driven by rising demand for longevity-focused therapies and growing research into age-related conditions like Alzheimer's and Parkinson's disease. Neurodegenerative disorders are also becoming a major area of focus for regenerative medicine as diseases such as Alzheimer's, Parkinson's, ALS, and multiple sclerosis continue to affect millions of people globally. Researchers are studying stem cell and regenerative neural therapies designed to repair damaged neurons, reduce inflammation in the brain, and potentially slow disease progression instead of simply managing symptoms. That push toward disease-modifying treatments is attracting substantial investment across both the biotech and pharmaceutical industries. Analysts estimate the broader neurodegenerative disease treatment market could grow from roughly $58.4 billion in 2025 to nearly $85 billion by 2032, while smaller niche markets tied to rare neurological disorders are also expected to expand as regenerative medicine technologies continue advancing through clinical development. Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy - Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a Master Cell Bank (MCB) of genetically modified cells that overexpress the α-Klotho protein. Now, the MCB will undergo comprehensive testing to confirm the absence of pathogenic viruses, as well as standard assays to verify the MCB is free from adventitious agents such as bacteria, mycoplasma, fungi, and yeast to meet regulatory expectations, including those set by the FDA. This testing will be conducted independently by a top-tier, accredited third-party provider, separate from Austrianova, Avaí Bio, and their combined joint venture, Klothonova. Following successful completion, the next step will be the generation of a "Working Cell Bank" (WCB) using α-Klotho protein–overexpressing cells derived from the MCB. These cells will be used to manufacture the final Cell-in-a-Box® encapsulated clinical product. A Master Cell Bank is a GMP-compliant, fully characterized, and homogeneous collection of vials derived from a single clone. It serves as the critical starting material for the scale-up and production of cell therapies, ensuring product consistency while reducing risk by protecting against contamination, degradation, extraneous agents, and genetic instability. By establishing and maintaining a high-quality MCB as the primary source for all Working Cell Banks under Good Manufacturing Practice (GMP) standards, Avaí Bio and Austrianova strengthen the foundation for a reliable, scalable, and sustainable supply chain. This milestone marks a significant step forward in Klothonova's mission to develop a sustainable, cell-based approach to restoring declining levels of the α-Klotho "longevity protein" associated with aging. The approach is intended to address both general aging and age-related conditions, including kidney disease, neurodegenerative disorders, and vascular diseases. "We are pleased that this first step in the production phase of α-Klotho producing cells has been successfully completed. We look forward to the completion of the subsequent steps needed to fulfill our commitment to deliver safe, effective treatments for the ever-burgeoning array of aging associated diseases," said Chris Winter, Chief Executive Officer of Avaí Bio. Dr Brian Salmons, Chief Executive Officer of Austrianova, added, "The Austrianova team is pleased to have completed the production of the α-Klotho protein expressing cells on behalf of Klothonova, our Joint Venture with Avaí Bio. We look forward to completing the next steps that will culminate with the production of Cell-in-a-Box® encapsulated clinical product for application to patients." This milestone represents the most recent progress under the joint venture agreement signed in September 2025, which established Klothonova as a Nevada-based company equally owned by Avaí Bio and Austrianova's affiliate, SG Austria Pte. Ltd. The joint venture is dedicated to the sustainable production of α-Klotho—often referred to as the "longevity protein"—a key regulatory protein widely recognized for its anti-aging properties and protective effects on multiple organs, delivered through encapsulated cell-based therapies for patients. CONTINUED… Read this and more news for Avaí Bio at: In other recent developments and happenings in the biotech market include: Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, recently announced that the first real-world evidence study of RYTELO® (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European Hematology Association (EHA) 2026 Congress. The retrospective and prospective investigator-sponsored study, conducted at the Moffitt Cancer Center, reported safety and clinical efficacy of imetelstat in advanced, heavily transfusion dependent patients with LR-MDS, including patients with extensive prior therapies and after luspatercept failure. Data from the retrospective portion of the study will be presented at the EHA 2026 Congress. "Imetelstat has become an important treatment option for patients with lower-risk myelodysplastic syndromes experiencing anemia and red blood cell transfusion burden, particularly in patients previously treated with ESAs or other therapies," said David A. Sallman, M.D., Associate Member, Malignant Hematology Department, Moffitt Cancer Center. "As treatment sequencing has emerged as an increasing area of focus in LR-MDS, real-world analyses such as this study can help provide additional context on how therapies are being used in routine clinical practice and across more diverse patient populations. We look forward to presenting these data at EHA 2026." BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, recently reported results from the Phase 1 clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. The full dataset, which includes a newly announced 60 mg once-daily cohort dosed for 21 days in participants with obesity and elevated inflammation, demonstrates that BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein (hsCRP) and consistent reductions across multiple inflammatory biomarkers, with a favorable tolerability profile. Notably, the 60 mg dose achieved hsCRP and other biomarker reductions comparable to the previously reported 120 mg dose. Based on the full Phase 1 dataset, BioAge intends to initiate a dose-ranging Phase 2 cardiovascular risk proof-of-concept trial in the first half of 2026, with data anticipated in the second half of 2026. Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, recently announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the Foundation Fighting Blindness' Retinal Therapeutics Innovation Summit 2026. The presentation, "Retinal Pigment Epithelium (RPE) Cell Therapy in Geographic Atrophy Secondary to Age-related Macular Degeneration: 3 Year Results from the Phase 1/2a Study," was presented by Eyal Banin, M.D., Ph.D., Center for Retinal and Macular Degenerations, Department of Ophthalmology Hadassah-Hebrew University Medical Center and Faculty of Medicine, on behalf of Roche and Genentech, a member of the Roche Group. "We are excited that our partners continue to collect data and highlight positive clinical results from the OpRegen RPE cell therapy phase 1/2a program," stated Brian M. Culley, Lineage CEO. "We remain confident in the potential of OpRegen to address a significant medical need from a single administration, especially because long term clinical outcomes from RPE cell therapy are challenging the long-held view that GA is an irreversible condition, and currently available therapies have not demonstrated a visual benefit. The results presented by Dr. Banin include OCT images which indicate partial restoration of outer retinal structure, including the re-appearance of a retinal pigment epithelial layer as well as features associated with recovery of photoreceptors. It remains notable that among patients who received extensive coverage of OpRegen RPE cells across the area of atrophy (n=5), anatomical and functional benefits have lasted for at least three years, outcomes consistent with meaningful disease stabilization and even improvement. We are excited to see any additional insights which our partners, Roche and Genentech, may uncover from the ongoing GAlette study, which is a surgical optimization study intended to assess the best way to deliver OpRegen cell therapy to patients with GA secondary to age related macular degeneration." Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients for broad accessibility, recently reported financial results for the first quarter ended March 31, 2026, and provided a business update. "We are incredibly excited and focused on initiating RECLAIM-LN, our Phase 2 potentially registrational clinical trial of FT819 for the treatment of lupus nephritis to provide eligible trial patients a truly accessible CAR T-cell treatment option," said Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer of Fate Therapeutics. "Our acceptance into the FDA's highly competitive CDRP Program, combined with our RMAT designation, reflects a recognition of the strength of our initial Phase 1 clinical data and provides a powerful regulatory foundation as we advance FT819 along an accelerated clinical pathway. With planned clinical advancement of FT819 on multiple fronts, next generation CAR T-cell programs entering clinical trials, a strong cash balance supporting our runway into 2028 and a team that continues to execute at the highest level, we believe 2026 will be a defining year for Fate Therapeutics." DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU expects to be compensated forty nine hundred dollars for news coverage of the current press releases issued by Avaí Bio, Inc. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements. Contact Information: Media Contact email: [email protected] - +1(561)325-8757 Logo - SOURCE Market News Updates 21% more press release views with Request a Demo

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. Companies mentioned: GT Biopharma, Inc. (NASDAQ: GTBP), Fate Therapeutics, Inc. (NASDAQ: FATE), Nkarta, Inc. (NASDAQ: NKTX), ImmunityBio, Inc. (NASDAQ: IBRX), INmune Bio, Inc. (NASDAQ: INMB) SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autologous CAR-T platforms that defined the cell therapy story of the prior decade. Clinical data from 2023 through 2026 has shown CRS incidence rates of less than 10% for NK therapies compared to 70%+ for some CAR-T products — a safety profile that has made NK platforms more suitable for outpatient and repeat dosing models.[1] Key Takeaways GT Biopharma (NASDAQ: GTBP) has now advanced three TriKE candidates into the clinic — GTB-3650 for CD33+ leukemias (AML/MDS), GTB-5550 for B7-H3-expressing solid tumors, and GTB-7550 in development for CD19+ lymphoid malignancies and autoimmune disease — all built on the Company's 2nd-generation TriKE platform under an exclusive worldwide license with the University of Minnesota. First patient was dosed in the GTB-5550 Phase 1 dose-escalation basket trial on May 14, 2026 — the first nanobody TriKE tested with more patient-friendly subcutaneous dosing, distinguishing it in a category that has historically required continuous infusion. The 2nd-generation TriKE platform has been described as 10–40 times more potent than 1st-generation TriKE, with all current development now focused on the 2nd-generation platform. The TriKE design engages CD16 on NK cells, embeds an IL-15 moiety to drive NK cell proliferation and persistence, and targets tumor-associated antigens with a nanobody arm. The publicly listed NK cell therapy and engager universe spans more than 140 companies globally, with cumulative funding into NK-focused biotech exceeding US$4.2 billion between 2020 and 2026 — a structural shift that has positioned NK cell therapeutics as one of the most actively funded immuno-oncology categories of the decade. What has changed in 2026 is not the thesis. It is the conversion of the thesis into clinical events. Cumulative funding flowing into NK-focused biotech firms now exceeds US$4.2 billion across 2020 to 2026, with a continued rise expected as clinical successes and regulatory clarity expand throughout the decade.[1] Inside that environment, the small set of companies that are actually dosing patients on NK cell engager platforms — not just talking about doing so — are the ones that the next phase of capital is now finding. GT Biopharma, Inc. (NASDAQ: GTBP) is one of them. Three TriKE Candidates In The Clinic, And A Platform Designed Around NK Cell Biology GT Biopharma's TriKE platform is built around a specific molecular architecture: a tri-specific killer engager that engages the CD16 activating receptor on natural killer cells using nanobody technology, embeds a human interleukin-15 (IL-15) crosslinker to enhance NK cell proliferation and persistence, and targets tumor-associated antigens with a dedicated targeting arm.[2] The CD16-anchored design mirrors the CD3-anchored design of T-cell engager therapeutics, but instead recruits and activates NK cells — an immune-cell category with structurally different cytokine-release and persistence profiles than T cells.[3] Unlike full-length tri-specific antibodies, TriKEs are small single-chain fusion proteins that bind the CD16 receptor of NK cells using nanobody technology, which has been shown in preclinical studies to produce a more potent and lasting response.[2] TriKEs form an immune synapse between the NK cell and the tumor cell, thereby inducing NK cell activation at that site, and NK cells mediate antibody-dependent cellular cytotoxicity (ADCC) through the highly potent CD16 activating receptor.[2] The molecules are also designed to be non-immunogenic, have quick clearance properties, and can be engineered rapidly to target a variety of tumor antigens — attributes the Company has framed as making them an ideal pharmaceutical platform for potentiated NK cell-based immunotherapies.[2] The platform now has three programs in clinical development. GTB-3650 is the Company's first 2nd-generation camelid nanobody TriKE, being tested clinically for the treatment of CD33-positive leukemias including acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).[3] GTB-5550, advanced into the clinic on May 14, 2026 with the first patient dosed, is the B7-H3-targeted program for solid tumors — and is the first dual-nanobody TriKE tested with more patient-friendly subcutaneous dosing.[4] GTB-7550 is in development for the treatment of CD19-positive lymphoid malignancies and autoimmune disease, with a tri-specific molecule composed of a camelid nanobody binding the CD16 receptor on NK cells, the single-chain variable fragment (scFv) of an anti-CD19 antibody, and an IL-15 linker.[3] Why The Subcutaneous Dosing And Nanobody Architecture Matter The GTB-5550 trial is the Company's first to deploy subcutaneous dosing, distinguishing it in an engager-therapy category where most molecules have historically required continuous infusion.[4] The patient-experience implications are significant: subcutaneous dosing is more compatible with outpatient delivery, lower-cost infrastructure, and repeat dosing — all of which expand both the addressable patient population and the commercial deployment options if the molecule clears clinical proof-of-concept. The nanobody architecture matters for a different set of reasons. Camelid nanobodies are substantially smaller than conventional antibody fragments, which contributes to faster biodistribution and clearance and — critically for solid tumor applications — potentially better penetration of tumor tissue.[2] As the Company has framed it, the TriKE molecules have an attractive biodistribution as a consequence of their smaller size, a factor that is expected to be important in the treatment of solid tumors.[2] Solid tumors have historically been the harder problem for NK-cell-based therapeutics; the GTB-5550 program is structured around the engineering choices designed to overcome the historical penetration limitations of larger engager molecules. How GT Biopharma Sits Inside The NK Cell Therapy Universe The publicly listed NK cell therapy and engager universe is large and structurally varied — spanning more than 140 companies across the global pipeline.[5] North America remains the largest regional market, capturing approximately 44% of global revenue in 2026 (more than US$235 million), driven by robust R&D investment, FDA Fast Track designations, and a high concentration of biotech companies operating across CAR-NK, NK cell engagers, and iPSC-derived NK platforms.[1] The region also leads in clinical development, hosting 45–50% of all global NK-cell-related trials.[1] Fate Therapeutics, Inc. (NASDAQ: FATE) is one of the leading publicly listed NK cell therapy companies, with a platform built around induced pluripotent stem cell (iPSC)-derived NK cell therapies for the treatment of cancer and autoimmune disease. Fate's iPSC platform offers an off-the-shelf manufacturing approach that contrasts mechanistically with engager molecule platforms like TriKE — but the platforms compete for the same broader NK-cell-based immuno-oncology opportunity. Fate represents the institutional-scale NK cell therapy comparable and provides one of the cleanest read-throughs for how the public market is currently valuing NK cell platforms at the cell-therapy end of the spectrum. Nkarta, Inc. (NASDAQ: NKTX) has been one of the more visible players in the CAR-NK space, developing engineered NK cell therapies derived from healthy donor NK cells for the treatment of hematologic and solid cancers.[6] As an off-the-shelf donor-derived NK cell therapy company, Nkarta sits in a mechanistically adjacent — but architecturally distinct — corner of the NK cell therapy universe from GT Biopharma's engager-platform approach. Nkarta's progression of NKX019 and related programs into pivotal-stage clinical work has helped to establish the CAR-NK reference comparable on which much of the broader public-market NK cell narrative now hangs. ImmunityBio, Inc. (NASDAQ: IBRX) has built an integrated immunotherapy platform that includes NK cell-based therapeutic approaches alongside cytokine, antibody, and vaccine technologies. The Company's broader oncology and infectious disease platform places it in a different scale and breadth of pipeline than a single-platform engager-focused company like GT Biopharma — but ImmunityBio's NK component contributes to the broader institutional case that NK cell biology is now actively translatable into approved therapeutics. ImmunityBio represents the integrated multi-modality NK platform comparable that helps frame how NK cell biology is being embedded into the broader oncology development environment in 2026. INmune Bio, Inc. (NASDAQ: INMB) is a clinical-stage immunology company developing therapies that target the innate immune system, including NK-cell-targeted programs. INmune's approach focuses on reprogramming the innate immune system to treat disease, with development programs spanning oncology and chronic inflammation. As a clinical-stage small-cap company with an innate-immunity focus, INmune represents one of the more directly comparable size-and-stage public companies for an NK-platform investment thesis — and helps establish a relevant market-cap reference frame for the kind of small-cap, single-platform NK biotech that GT Biopharma also represents. Across all four comparables, the pattern is clear: NK-cell-based immunotherapy has reached the threshold where mechanism diversity inside the category now matters — and the four comparables span four meaningfully different approaches to harnessing NK cell biology. GT Biopharma's TriKE platform offers the engager-molecule entry point into that broader investment landscape. The Late-2026 Catalyst Window Phase 1 trial updates for GTB-5550 are anticipated in the second half of 2026 as enrollment progresses through dose escalation cohorts.[7] The Company's cash balance of approximately US$9 million as of March 31, 2026 is anticipated to provide sufficient runway through Q4 2026.[7] In other words, the next clinical readouts and the next capital-markets event are both visible inside the next two to three quarters — a defined window in which the platform's translational thesis will be tested against actual Phase 1 patient data. For investors looking at a single-platform clinical-stage NK cell engager exposure with three candidates in the clinic, a 2nd-generation platform described as 10–40 times more potent than its predecessor, and a defined 2H 2026 catalyst window — GT Biopharma offers a small-cap, focused entry point into one of the most actively funded immuno-oncology categories of the decade. The broader NK cell therapy universe will continue to develop along multiple parallel mechanisms; the question for GT Biopharma specifically is whether the TriKE platform can produce the kind of Phase 1 signal in the dose-escalation cohorts that converts platform thesis into clinical proof. The next read on that question arrives across the back half of 2026. Contact Equity Insider [email protected] 604-265-2871 Article Sources [1] [2] [3] [4] [5] [6] [7] DISCLAIMER NOTICE Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by Equity Insider on behalf of MIQ. MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Direct Marketing Group ("CDMG"). There may be 3rd parties who may have shares of GT Biopharma, Inc. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. The owner/operator of MIQ currently owns shares of GT Biopharma, Inc. that were purchased in the open market and reserves the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of GT Biopharma, Inc. by CDMG; this is a digital media distribution. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo - SOURCE Equity Insider 21% more press release views with Request a Demo